Patents by Inventor Michael N. Alonso
Michael N. Alonso has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250145575Abstract: The invention provides macromolecule-supported compounds of Formula I comprising a macromolecule linked by conjugation to one or more 8-sulfonyl-2-aminobenzazepine derivatives. The invention also provides 8-sulfonyl-2-aminobenzazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the macromolecule-supported compounds through a linker or linking moiety. The invention further provides methods of treating cancer with the macromolecule-supported compounds.Type: ApplicationFiled: February 8, 2023Publication date: May 8, 2025Applicant: BOLT BIOTHERAPEUTICS, INC.Inventors: Shelley Erin ACKERMAN, Michael N. ALONSO, Romas KUDIRKA, Brian SAFINA, Ganapathy SARMA
-
Publication number: 20250127914Abstract: The invention provides immunoconjugates of Formula. (I) comprising an antibody linked by conjugation to one or more 8-sulfonyl-2-aminobenzazepine derivatives. The invention also provides 8-sulfonyl-2-aminobenzazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.Type: ApplicationFiled: February 8, 2023Publication date: April 24, 2025Applicant: BOLT BIOTHERAPEUTICS, INC.Inventors: Shelley Erin ACKERMAN, Michael N. ALONSO, Romas KUDIRKA, Brian SAFINA, Ganapathy SARMA
-
Publication number: 20250000995Abstract: The invention provides immunoconjugates comprising a cysteine-mutant antibody covalently attached to one or more TLR agonist moieties by a linker. The invention further provides methods of treating cancer with the immunoconjugates.Type: ApplicationFiled: October 28, 2022Publication date: January 2, 2025Applicant: BOLT BIOTHERAPEUTICS, INC.Inventors: Shelley Erin ACKERMAN, Michael N. ALONSO, Jan GRUNEWALD, Romas KUDIRKA, Brian SAFINA, Ganapathy SARMA
-
Publication number: 20240238430Abstract: The invention provides immunoconjugates of Formula I comprising an anti-CEA antibody linked by conjugation to one or more 8-phenyl-2-aminobenzazepine derivatives. The invention also provides 8-phenyl-2-aminobenzazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.Type: ApplicationFiled: December 10, 2021Publication date: July 18, 2024Applicant: BOLT BIOTHERAPEUTICS, INC.Inventors: Shelley Erin ACKERMAN, Michael N. ALONSO, David DORNAN, Marcin KOWANETZ, Romas KUDIRKA, Arthur LEE, William MALLET, Brian SAFINA, Matthew ZHOU
-
Publication number: 20240091370Abstract: The invention provides immunoconjugates of Formula I comprising an anti-HER2 antibody linked by conjugation to one or more 8-Het-2-aminobenzazepine derivatives. The invention also provides 8-Het-2-aminobenzazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.Type: ApplicationFiled: December 10, 2021Publication date: March 21, 2024Applicant: BOLT BIOTHERAPEUTICS, INC.Inventors: Shelley Erin ACKERMAN, Michael N. ALONSO, Romas KUDIRKA, Arthur LEE, Brian SAFINA, Matthew ZHOU
-
Publication number: 20240042050Abstract: The invention provides immunoconjugates of Formula I comprising an anti-HER2 antibody linked by conjugation to one or more 8-phenyl-2-aminobenzazepine derivatives. The invention also provides 8-phenyl-2-aminobenzazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.Type: ApplicationFiled: December 10, 2021Publication date: February 8, 2024Applicant: BOLT BIOTHERAPEUTICS, INC.Inventors: Shelley Erin ACKERMAN, Michael N. ALONSO, Romas KUDIRKA, Arthur LEE, Brian SAFINA, Matthew ZHOU
-
Publication number: 20240033370Abstract: The invention provides immunoconjugates of Formula I comprising an anti-PD-L1 antibody linked by conjugation to one or more 8-Cyc-2-aminobenzazepine derivatives. The invention also provides 8-Cyc-2-aminobenzazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.Type: ApplicationFiled: December 10, 2021Publication date: February 1, 2024Applicant: BOLT BIOTHERAPEUTICS, INC.Inventors: Shelley Erin ACKERMAN, Michael N. ALONSO, David DORNAN, Marcin KOWANETZ, Romas KUDIRKA, Arthur LEE, William MALLET, Brian SAFINA, Matthew ZHOU
-
Publication number: 20230165968Abstract: The invention provides methods for treating cancer in a subject comprising administering an immunoconjugate of formula: Ab-[TA]r or a pharmaceutically acceptable salt thereof, wherein “Ab” is an antibody construct that has an antigen binding domain that binds human epidermal growth factor receptor type 2 (HER2) and “TA” is a therapeutic agent of formula: wherein n is from about 2 to about 25 and r is an average therapeutic agent to antibody ratio from 1 to 10, to a subject having cancer.Type: ApplicationFiled: February 25, 2021Publication date: June 1, 2023Applicant: BOLT BIOTHERAPEUTICS, INC.Inventors: Shelley Erin ACKERMAN, Michael N. ALONSO, David DORNAN, Marcin L. KOWANETZ, Robert S. SIKORSKI, Steven A. SMITH
-
Publication number: 20230086603Abstract: The invention relates to programmed death-ligand 1 (PD-L1) binding agents, nucleic acids comprising the inventive binding agents, vectors and cells comprising the inventive nucleic acids, and compositions thereof. The invention also relates to methods of producing the inventive binding agents, methods for treating a disease, disorder, or condition in a mammal, and methods for enhancing or reducing or inhibiting an immune response in a mammal.Type: ApplicationFiled: January 21, 2021Publication date: March 23, 2023Applicant: BOLT BIOTHERAPEUTICS, INCInventors: Michael N. ALONSO, David DORNAN, Karla HENNING, Justin KENKEL, Marcin KOWANETZ, Heidi LEBLANC, William MALLET
-
Publication number: 20230069055Abstract: The invention relates to programmed death-ligand 1 (PD-L1) binding agents, nucleic acids comprising the inventive binding agents, vectors and cells comprising the inventive nucleic acids, and compositions thereof. The invention also relates to methods of producing the inventive binding agents, methods for treating a disease, disorder, or condition in a mammal, and methods for enhancing or reducing or inhibiting an immune response in a mammal.Type: ApplicationFiled: January 21, 2021Publication date: March 2, 2023Applicant: BOLT BIOTHERAPEUTICS, INCInventors: Michael N. ALONSO, David DORNAN, Karla HENNING, Justin KENKEL, Marcin KOWANETZ, Heidi LEBLANC, William MALLET
-
Publication number: 20220347311Abstract: The invention provides an immunoconjugate of formula: or pharmaceutically acceptable salt thereof, wherein subscript r is an integer from 1 to 10, subscript n is an integer from about 2 to about 25, and “Ab” is an antibody construct that has an antigen binding domain that binds HER2. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.Type: ApplicationFiled: June 30, 2022Publication date: November 3, 2022Applicants: Bolt Biotherapeutics, Inc., The Board of Trustees of The Leland Stanford Junior UniversityInventors: Shelley Erin Ackerman, Michael N. Alonso, David Y. Jackson, Arthur Lee, Edgar George Engleman
-
Publication number: 20220315537Abstract: The application provides macromolecule-supported compounds of Formula I or III comprising a macromolecular support linked by conjugation to one or more aminobenzazepine derivatives. The application also provides aminobenzazepine derivative intermediate compositions of Formula II comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the macromolecule-supported compounds through a linker or linking moiety. The application further provides compositions comprising the macromolecule-supported compounds, as well as methods of treating cancer with the macromolecule-supported compounds.Type: ApplicationFiled: June 12, 2020Publication date: October 6, 2022Applicant: Bolt Biotherapeutics, Inc.Inventors: Shelley Erin Ackerman, Michael N. Alonso, Romas Kudirka, Arthur Lee, Brian Safina, Matthew Zhou
-
Patent number: 11400164Abstract: The invention provides an immunoconjugate of formula: or pharmaceutically acceptable salt thereof, wherein subscript r is an integer from 1 to 10, subscript n is an integer from about 2 to about 25, and “Ab” is an antibody construct that has an antigen binding domain that binds HER2. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.Type: GrantFiled: September 2, 2021Date of Patent: August 2, 2022Assignees: Bolt Biotherapeutics, Inc., The Board of Trustees of The Leland Stanford Junior UniversityInventors: Shelley Erin Ackerman, Michael N. Alonso, David Y. Jackson, Arthur Lee, Edgar George Engleman
-
Publication number: 20220226492Abstract: The invention provides an immunoconjugate of formula (I) or (II). Antibody-adjuvant immunoconjugates of the invention, comprising an antibody construct that has an antigen binding domain that binds human epidermal growth factor receptor 2 (“HER2”) linked to one or more adjuvants, demonstrate superior pharmacological properties over conventional antibody conjugates. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.Type: ApplicationFiled: March 13, 2020Publication date: July 21, 2022Applicants: Bolt Biotherapeutics, Inc., The Board of Trustees of The Leland Stanford Junior UniversityInventors: Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Romas Kudirka, Arthur Lee, Brian Safina, Matthew Zhou, Edgar George Engleman
-
Publication number: 20220226491Abstract: The invention provides an immunoconjugate of formula (I) or (II). Antibody-adjuvant immunoconjugates of the invention, comprising an antibody construct that has an antigen binding domain that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants, demonstrate superior pharmacological properties over conventional antibody conjugates. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.Type: ApplicationFiled: March 13, 2020Publication date: July 21, 2022Applicants: Bolt Biotherapeutics, Inc., The Board of Trustees of The Leland Stanford Junior UniversityInventors: Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Justin Kenkel, Romas Kudirka, Arthur Lee, Brian Safina, Matthew Zhou, Edgar George Engleman
-
Publication number: 20220195066Abstract: The invention provides immunoconjugates of Formula I comprising an anti-CEA antibody linked by conjugation to one or more 8-Het-2-aminobenzazepine derivatives. The invention also provides 8-Het-2-aminobenzazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.Type: ApplicationFiled: December 9, 2021Publication date: June 23, 2022Applicant: BOLT BIOTHERAPEUTICS, INC.Inventors: Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Marcin Kowanetz, Romas Kudirka, Arthur Lee, William Mallet, Brian Safina, Matthew Zhou
-
Publication number: 20220152215Abstract: The invention provides an immunoconjugate of formula (I) or (II) Antibody-adjuvant immunoconjugates of the invention, comprising an antibody construct that has an antigen binding domain that binds carcinoembryonic antigen (“CEA”) linked to one or more adjuvants, demonstrate superior pharmacological properties over conventional antibody conjugates. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.Type: ApplicationFiled: March 13, 2020Publication date: May 19, 2022Applicants: Bolt Biotherapeutics, Inc., The Board of Trustees of The Leland Stanford Junior UniversityInventors: Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Marcin Kowanetz, Romas Kudirka, Arthur Lee, William Mallet, Brian Safina, Matthew Zhou, Edgar George Engleman
-
Publication number: 20220143012Abstract: The invention provides a macromolecule-supported compound of formula (I) or (II). Macromolecule-supported compounds of the invention, comprising macromolecular support linked to one or more TLR agonists, are recognized by TLRs (e.g., TLR7 and/or TLR8) with high affinity providing utility in therapeutics, diagnostics, and chemical assays. The invention further provides compositions comprising and methods of treating cancer with the macromolecule-supported compounds.Type: ApplicationFiled: March 13, 2020Publication date: May 12, 2022Applicants: Bolt Biotherapeutics, Inc., The Board of Trustees of The Leland Stanford Junior UniversityInventors: Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Justin Kenkel, Romas Kudirka, Arthur Lee, Brian Safina, Matthew Zhou, Edgar George Engleman
-
Publication number: 20220001022Abstract: The invention provides an immunoconjugate of formula: or pharmaceutically acceptable salt thereof, wherein subscript r is an integer from 1 to 10, subscript n is an integer from about 2 to about 25, and “Ab” is an antibody construct that has an antigen binding domain that binds HER2. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.Type: ApplicationFiled: September 2, 2021Publication date: January 6, 2022Applicants: Bolt Biotherapeutics, Inc., The Board of Trustees of The Leland Stanford Junior UniversityInventors: Shelley Erin Ackerman, Michael N. Alonso, David Y. Jackson, Arthur Lee, Edgar George Engleman
-
Publication number: 20210284750Abstract: A method for producing an immunoconjugate, the method comprising combining one or more compounds of Formula I and an antibody of Formula II, wherein Formula II is an antibody with one or more lysine residues, in an aqueous solution buffered at a pH of about 7.5 to about 9 until at least 33 mol % of the one or more compounds of Formula I is conjugated to the antibody of Formula II to provide the immunoconjugate of Formula III, wherein Adj is an adjuvant, Z is —CH2—, —C(O)NH—, —C(O)O—, or —C(O)—, L is a linker, E is an ester, and r is the average number of adjuvants attached to the antibody and is a positive number up to about 8, in a first buffered aqueous solution.Type: ApplicationFiled: April 16, 2018Publication date: September 16, 2021Applicant: Bolt Biotherapeutics, Inc.Inventors: David Y. Jackson, Michael N. Alonso, Arthur Lee, Richard P. Laura